These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 2429444

  • 1. [Effective complexes of the antileukemic enzyme L-asparaginase with dextran sulfate].
    Karsakevich AS, Dauvarte AZh, Zvirgzda IK, Lebedeva LV, Vina IA.
    Vopr Med Khim; 1986; 32(4):47-51. PubMed ID: 2429444
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA, Morgenstern B, Capizzi RL.
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [Abstract] [Full Text] [Related]

  • 5. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
    Abuchowski A, Kazo GM, Verhoest CR, Van Es T, Kafkewitz D, Nucci ML, Viau AT, Davis FF.
    Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice.
    Vadlamudi S, Krishna B, Reddy VV, Goldin A.
    Cancer Res; 1973 Sep; 33(9):2014-9. PubMed ID: 4725366
    [No Abstract] [Full Text] [Related]

  • 9. [Biochemical and genetic aspects of the use of L-asparaginase as an antileukemic factor].
    Medvedev ZhA.
    Usp Sovrem Biol; 1971 Sep; 71(2):208-19. PubMed ID: 4935597
    [No Abstract] [Full Text] [Related]

  • 10. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia.
    Savoca KV, Davis FF, van Es T, McCoy JR, Palczuk NC.
    Cancer Biochem Biophys; 1984 Sep; 7(3):261-8. PubMed ID: 6488153
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J, Schmid FA, Old LJ, Stockert E.
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [Abstract] [Full Text] [Related]

  • 13. [L-asparaginase--first specific cytostatic].
    Marquardt H.
    Arzneimittelforschung; 1968 Nov; 18(11):1380-6. PubMed ID: 4885156
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Amino acid content of L5178Y and L5178Y/L-ASE cells after L-asparaginase treatment.
    Keefer JF, Moraga DA, Schuster SM.
    Biochem Med; 1985 Oct; 34(2):135-50. PubMed ID: 4084239
    [Abstract] [Full Text] [Related]

  • 17. Experimental studies with L-asparaginase in mouse leukemias.
    Burchenal JH, Benvenisti D, Dollinger M.
    Recent Results Cancer Res; 1970 Oct; 33():102-13. PubMed ID: 5292716
    [No Abstract] [Full Text] [Related]

  • 18. L-asparaginase--antileukemia agent.
    Bukhari SZ, Yaqub M.
    J Pak Med Assoc; 1977 Jan; 27(1):262-4. PubMed ID: 19639
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Modified Heparin-Binding L-Asparaginase of Wolinella succinogenes.
    Sannikova EP, Bulushova NV, Cheperegin SE, Gubaydullin II, Chestukhina GG, Ryabichenko VV, Zalunin IA, Kotlova EK, Konstantinova GE, Kubasova TS, Shtil AA, Pokrovsky VS, Yarotsky SV, Efremov BD, Kozlov DG.
    Mol Biotechnol; 2016 Sep; 58(8-9):528-39. PubMed ID: 27198565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.